Yunnan Baiyao Group Co., Ltd. (hereinafter referred to as "the Company") and all members of the Board of Directors guarantee that the content of this information disclosure is true, accurate, and complete, without false records, misleading statements, or significant omissions.
The Company recently received notification from the U.S. Food and Drug Administration (hereinafter referred to as "FDA") that the clinical trial application (hereinafter referred to as "IND") for INB301 injection (hereinafter referred to as "the Product") submitted by the Company has been approved by the FDA, allowing the commencement of clinical trials aimed at developing a treatment for cancer cachexia.